132 related articles for article (PubMed ID: 24229718)
1. Cervical cancer screening, human papillomavirus vaccination practices and current infrastructure in Israel.
Schejter E; Bornstein J; Siegler E
Vaccine; 2013 Nov; 31 Suppl 8():I42-5. PubMed ID: 24229718
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
Ginsberg GM
Vaccine; 2013 Nov; 31 Suppl 8():I46-52. PubMed ID: 24229719
[TBL] [Abstract][Full Text] [Related]
4. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
6. Barriers to human papillomavirus vaccine acceptability in Israel.
Fisher WA; Laniado H; Shoval H; Hakim M; Bornstein J
Vaccine; 2013 Nov; 31 Suppl 8():I53-7. PubMed ID: 24229720
[TBL] [Abstract][Full Text] [Related]
7. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
8. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
9. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
10. Screening for cervical cancer and human papillomavirus vaccination in Israel: recommendations.
Bornstein J; Fisher WA; Ginsberg GM; Shavit O; Schejter E; Diaz M; Bosch FX
Vaccine; 2013 Nov; 31 Suppl 8():I58-60. PubMed ID: 24229721
[No Abstract] [Full Text] [Related]
11. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries.
Sancho-Garnier H; Khazraji YC; Cherif MH; Mahnane A; Hsairi M; El Shalakamy A; Osgul N; Tuncer M; Jumaan AO; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G51-7. PubMed ID: 24331820
[TBL] [Abstract][Full Text] [Related]
12. Attitudes toward cervical cancer screening among women receiving human papillomavirus vaccination in a university-hospital-based community: interim 2-year follow-up results.
Miyagi E; Sukegawa A; Motoki Y; Kaneko T; Maruyama Y; Asai-Sato M; Numazaki R; Mizushima S; Hirahara F
J Obstet Gynaecol Res; 2014 Apr; 40(4):1105-13. PubMed ID: 24428631
[TBL] [Abstract][Full Text] [Related]
13. Burden of human papillomavirus infection and related diseases in Israel.
Shavit O; Roura E; Barchana M; Diaz M; Bornstein J
Vaccine; 2013 Nov; 31 Suppl 8():I32-41. PubMed ID: 24229717
[TBL] [Abstract][Full Text] [Related]
14. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
16. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
17. Modeling the impact of screening policy and screening compliance on incidence and mortality of cervical cancer in the post-HPV vaccination era.
de Blasio BF; Neilson AR; Klemp M; Skjeldestad FE
J Public Health (Oxf); 2012 Dec; 34(4):539-47. PubMed ID: 22707556
[TBL] [Abstract][Full Text] [Related]
18. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM; Mullins RM
Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
[TBL] [Abstract][Full Text] [Related]
19. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
20. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]